



INVESTOR FORUM

October 22-23, 2019

The Westin St. Francis • San Francisco, CA

ACCELERATE
Discovery.
AMPLIFY
Returns.

#BIF19

bio.org/investorforum

EVENT BROCHURE



The BIO Investor Forum

is an international biotech investor conference focused on investment trends and opportunities in life sciences, with unbiased emphasis on venture-stage growth and emerging public companies as well as those poised to join the growth “watch list” in 2020.

BIO Investor Forum features include:



- **Public and venture-stage** company presentations.
- **Expert-led workshops** on the latest market and investment opportunities with emphasis on drug and technology development.
- **BIO One-on-One Partnering™** meetings.
- **Premier opportunity to network** with industry executives and investors focused exclusively on life sciences.



Audience Demographics

TARGET AUDIENCE


Private equity and public investors, research analysts, and industry executives focused on investment and business development opportunities in the life sciences.







Audience Demographics, CONTINUED



“Like being at JPM without the crowds.”



#BIF19 has investors representing **11** countries



#BIF19 has a record share of private company investors

BIO One-on-One Partnering



BIO's One-on-One Partnering™ system is the interactive platform that allows you to increase your productivity, discover new investment and licensing opportunities, and expand your business potential worldwide.

- **Pre-schedule** 30-minute private 1x1 meetings
- **Source** potential collaborations and funding opportunities with an international audience
- **Communicate** directly with prospective investors and C-level executives in biotech and pharma
- **Search** company and investor profiles for potential business partnerships



Partnering activity is up
MORE THAN 60%



Accepted meetings are up
BY OVER 130%



More than **50 COMPANIES** are new
in the partnering system




Why Companies Attend

- **Meet** one-on-one with new and current investors, analysts, and partnering companies.
- **Get the pulse** on the latest life sciences investment trends from sophisticated investment and company executives.
- **Showcase** your company story in presentations to qualified investors.
- **Network** with peers, investors and potential partners.

Why Investors Attend

- **Hear from and meet** with executives at the top life sciences growth companies.
- **Evaluate** fresh investment opportunities including compatible, complementary and competitive companies.
- **Benefit** from candid panel discussions with leading clinical experts and investigators with insights on pipeline research and clinical practice.
- **Get a 'big picture' overview** of the industry and the issues affecting product innovation, capitalization, and commercialization.

2018 BIO Investor Forum



“The investors were great. I don’t know what similar access I’ll have to such a collection again.”

“Excellent forum for meeting investors or alliance partners for biotech deals.”



2019 Advisory Committee



Mahima Agochiya, PhD
Business Development &
Program Manager
SPARK Translational
Research Program,
Stanford University



Janice Bourque
Managing Director,
Life Sciences
Hercules Technology
Growth Capital



Jason Camm
Managing Director and
Chief Medical Officer
Thiel Capital LLC



Alice Chen, PhD
Vice President
Accelerator Life
Science Partners



Jung Choi
Chief Business & Strategy Officer
Global Blood Therapeutics



Shelley Chu, MD, PhD
Partner
Abingworth



Rajeev Dadoo, PhD
Partner
S.R. One Limited



Gini Deshpande, PhD
Founder & Chief
Executive Officer
NuMedii



Jack Florio
Partner, Strategy
Consulting Practice
Deallus



Julie Gilmore, PhD
Chief Operating Officer,
Lilly Research Labs
Eli Lilly and Company



Tao Huang, PhD, JD
Venture Partner
Cenova Capital



Charlotte Hubbert, PhD
Partner
Gates Foundation
Venture Capital



Alexis Ji, PhD
Partner
Illumina Ventures



Margaret Kim
Executive Director,
Life Sciences
JPMorgan Chase & Co.



Ravi Kiron, PhD
Head, BioPharma External
Innovation
EMD Serono



Jennifer Landress
Senior Vice President and
Chief Operating Officer
Biocom



Bill Martin, PhD
President and
Chief Operating Officer
Blackthorn Therapeutics



Samantha Miller, MSc, MBA
Co-Founder and Chief Operating
Officer, Cadence Health;
Chief Business Officer
InCarda Therapeutics



Carolyn Ng, PhD
Managing Director
Vertex Ventures HC



Peter Noymer, PhD
Former President and CEO
Kedallion Therapeutics;
Independent Advisor

2019 Advisory Committee, CONTINUED



Stephen Ritoch

Chairman &
Chief Executive Officer
Blaise Group International



John Ryan

Managing Director
Wells Fargo Strategic Capital



Andrew Setikas

Senior Vice President, Business
Development and Strategy
**California Life Sciences
Association**



Mahendra G. Shah, PhD

Managing Director
Vivo Capital



Ruchita Sinha

Senior Director of Investments
Sanofi Ventures



Komathi Stem

Founder & Chief
Executive Officer
monARC Bionetworks



Samuel Wu, MD, PhD

Managing Director
Acuris Partners



Asish Xavier, PhD

Vice President,
Venture Investments
**Johnson & Johnson
Innovation – JJDC, Inc.**

BIO SPARK Showcase

The BIO SPARK Showcase aims to provide an excellent opportunity for academic researchers in the SPARK network to showcase drug development programs that are ready for partnering or venture funding.

The BIO Investor Forum is historically well attended by the venture arms and business development units of major pharmaceutical companies, smaller specialty pharma/biotech companies looking to add to their pipelines, start-ups, and many early stage venture capital firms, making it the ideal setting for early stage assets from the university setting. Academics interested in partnering will present their programs and also have one-on-one discussions with interested parties.

SPARK
PARTNERING

Participation in the BIO SPARK Showcase is free.

Separate registration required.
Please RSVP at
<http://bit.ly/BIOSPARK19rsvp>

Presentation Schedule

Monday, October 21, 2019 • 12:45pm - 6:30pm

SPARK Affiliate and Program	
12:45 PM - 12:50 PM	Welcome from SPARK Translational Research Program, Stanford Medicine Kevin Grimes, MD, <i>Co-Director</i>
12:50 PM - 1:10 PM	SPARK at Stanford – Bacchus Therapeutics Novel Treatment for Kidney Cancer <i>Arvin Gouw</i>
1:10 PM - 1:30 PM	SPARK Colorado A Breakthrough Therapy for Triple-Negative Breast Cancer <i>TBD</i>
1:30 PM - 1:50 PM	SPARK Taiwan Selective Top2 Chemotherapeutics <i>TBD</i>
1:50 PM - 2:10 PM	SPARK Norway Novel Therapy for Ischemic Reperfusion <i>TBD</i>
2:10 PM - 2:30 PM	SPARK Japan Revolutionizing the Way We Treat Heart Failure <i>TBD</i>
2:30 PM - 2:40 PM	Break
2:40 PM - 3:00 PM	SPARK Japan Gene Engineering Tools for Optical Control of Crispr/Cas9-Cpf1, Cre-Loxp System <i>TBD</i>
3:00 PM - 3:20 PM	SPARK Norway A Novel Vaccine Platform Against Influenza <i>Gunnveig Grødeland</i>

Presentation Schedule, CONTINUED

3:20 PM - 3:40 PM	Stanford University Small Molecule for the Treatment of Type 1 Diabetes <i>Andy Wardle</i>
3:40 PM - 4:00 PM	SPARK Germany Recombinant Human Neuregulin1 (Rhng1) for the Treatment Of Schwann Cell-Derived Nerve Sheath Tumors <i>Helen Morrison</i>
4:00 PM - 4:10 PM	Break
4:10 PM - 4:30 PM	SPARK Stanford – Rejuvenation Technologies Transient Telomere Extension to Treat Liver Failure in Dyskeratosis Congenita Patients <i>John Ramunas</i>
4:30 PM - 4:50 PM	SPARK Finland Novel treatment modality for Limbal Epithelial Stem Cell Deficiency <i>Anni Möro</i>
4:50 PM - 5:10 PM	SPARK Norway Repositioning of Existing Drugs to Prevent Ventricular Arrhythmias <i>TBD</i>
5:10 PM - 5:30 PM	SPARK at Stanford Charge-Altering Releasable Transporters (CARTS): New Materials enable a New Platform Technology for Gene Delivery, Vaccinations, and Cancer Immunotherapy <i>Tim Blake</i>
5:30 PM - 5:50 PM	SPARK Colorado Targeting AMPK in Glioblastoma <i>TBD</i>
5:30 PM - 6:30 PM	SPARK Reception <i>Victors</i>



Tuesday Schedule of Events

Schedule subject to change and speakers continue to be updated.

To see the full list of speakers, please visit <http://bit.ly/BIF19speakers>

Tuesday, October 22, 2019	
6:30 AM - 5:30 PM	Partnering Customer Service Desk Sussex Room
7:00 AM - 7:55 AM	Networking Breakfast California West Room
7:20 AM - 5:30 PM	Satellite Partnering Desk 3rd & 4th Floor
7:30 AM - 5:30 PM	Partnering Meetings 3rd & 4th Floor
7:30 AM - 5:30 PM	Partnering Hospitality Suite Room 334
9:00 AM - 4:15 PM	Company Presentations Elizabethan Rooms A-D & Yorkshire Room

Sessions at a Glance	
8:30 AM - 9:40 AM	The Next Wave of Cancer Treatments: Allogeneic Cell Therapies and Other Pioneers
9:45 AM - 10:40 AM	Private Investors' Incubators for University-Sourced Ideas
10:45 AM - 11:40 AM	Gene Therapies: Pipelines Into A New Era for Patients
12:30 PM - 1:25 PM	Plenary: Policy Outlook on Biotech Investment from China
2:00 PM - 2:55 PM	Fireside Chat: Jean-Jacques Bienaimé, Chairman & CEO, BioMarin
3:00 PM - 3:55 PM	Recruiting Talent to Meet Corporate Board Requirements and Representation Goals
4:00 PM - 4:55 PM	View from the Board: To IPO Now or Not?

Tuesday, October 22, 2019 • 8:30 AM - 9:40 AM

THERAPEUTIC PANEL

California East Room

The Next Wave of Cancer Treatments: Allogeneic Cell Therapies and Other Pioneers

Moderator: Amanda Murphy, *Biotechnology Analyst, BTIG*

Panelists: Rafael Amado, MD, *EVP of Research & Development and Chief Medical Officer, Allogene*
Benjamin R. Cowen, PhD, *President & CEO, ImmunoMet*
Jie D'Elia, PhD, *Executive Director, Business Development Transactions, Bristol-Myers Squibb*
Lalo Flores, PhD, *Chief Executive Officer, Century Therapeutics*
Gary Lee, PhD, *Chief Scientific Officer, Senti Bio*
Kanya Rajangam, MD, PhD, *Senior Vice President and Chief Medical Officer, Nkarta Therapeutics*

As the industry continues to do revolutionary research on cancer, a host of new treatment options for therapies are showing promising data to disrupt the spread of tumors and inching us closer to a world where cancers can be cured. This panel reviews emerging treatment options in cancer, including the next wave of CAR-T, NK cell, and other pioneering approaches, highlighting promises enabled by each and the challenges to be resolved on the path to approvals and helping patients worldwide.

Tuesday, October 22, 2019 • 9:45 AM - 10:40 AM

BUSINESS PANEL

California East Room

Private Investors' Incubators for University-Sourced Ideas

Moderator: Catherine Vorwald, *Director of Life Sciences, The Labs @ Sterling Bay*

Panelists: Mark S. Blumenkranz, MD, *Managing Director, Lagunita Biosciences*
Jennifer Cochran, PhD, *Executive Chairman, xCella Biosciences*
Chris Garabedian, *Chairman and CEO, Xontogeny; Portfolio Manager—Venture, Perceptive Advisors*
Julie Gilmore, PhD, *Chief Operating Officer, Lilly Research Labs, Eli Lilly and Company*
Kevin Grimes, MD, *Co-Director, SPARK Translational Research Program, Stanford University*
Satish Jindal, PhD, *Managing Director, BioMotiv*

Recognizing a persistent “valley of death” in funding for medical research past the government-grant stage, several organizations have recently launched specialized investment vehicles. These vehicles are specifically designed to support translational research for university-sourced ideas to become independent companies capable of moving biological ideas into human drug development and to attract conventional venture investors. Hear from investors, academics, and entrepreneurs pursuing these new approaches that resolve critical bottlenecks as they work to lower initial project risks and accelerate progress through proof-of-concept.

Tuesday, October 22, 2019 • 9:30 AM - 10:00 AM

MORNING NETWORKING REFRESHMENTS

California West Room

Tuesday, October 22, 2019 • 10:45 AM - 11:40 AM

THERAPEUTIC PANEL

California East Room

Gene Therapies: The Pipeline Towards a New Era for Patients

Moderator: Shyam Patel, PhD, *Associate Director, Portfolio Development & Review, California Institute for Regenerative Medicine (CIRM)*

Panelists: Kathie Bishop, PhD, *Chief Scientific Officer, Locana*
Jason Fontenot, PhD, *Senior Vice President of Cell Therapy, Sangamo Therapeutics*
Alexandra Forbes, PhD, *President and Chief Executive Officer, MeiraGTx*
Michelle Gilson, *Principal, Cannacord Genuity Inc.*
Gary Lee, PhD, *Chief Scientific Officer, Senti Bio*
Michael Narachi, MBA, *President and CEO, CODA Biotherapeutics*

Gene therapies have the potential to increase the healthspan of patients and offer new approaches to treating diseases, with sizable pipelines in development and the first commercialized therapies revealing preliminary lessons about value and access. Early leaders in the field have focused on rare diseases which continues to open the pathway for other treatments in more widespread diseases. Attend this session to hear from several developers working to change patients' genetics and lives to become their own hopeful cures.

Tuesday, October 22, 2019 • 12:30 PM - 1:25 PM

OPENING PLENARY

California East Room

Policy Outlook on Biotech Investment from China

Moderator: Cameron Arterton, *Vice President, Tax Policy, Biotechnology Innovation Organization*

Panelists: Helen Chen, *Greater China Managing Partner, Head of L.E.K. China and Asia Life Sciences, L.E.K. Consulting*
Joshua Gruenspecht, *Of Counsel, Wilson Sonsini Goodrich & Rosati*
James Huang, *Managing Partner, Kleiner Perkins Caufield & Byers China*

According to Pitchbook, Chinese venture capital investment in U.S. biotechs has declined more than 60% in the first half of 2019. The increased review of the Committee on Foreign Investment in the US (CFIUS) on transactions, national security concerns, and trade negotiations have created a new landscape for cross-border business. The session will explore how biotech companies can continue to raise capital, the proposed rulemaking from CFIUS in the coming months, and a pathway for companies to remain innovative while CEOs and investors navigate these changes.

Tuesday, October 22, 2019 • 2:00 PM - 2:55 PM

FIRESIDE CHAT

California East Room



Fireside Chat with Jean-Jacques Bienaimé, Chairman and CEO, BioMarin

Moderator: Simone Fishburn, PhD, *Vice President and Editor in Chief, BioCentury Inc.*

Tuesday, October 22, 2019 • 2:00 PM - 3:00 PM

AFTERNOON NETWORKING REFRESHMENTS

California West Room

Tuesday, October 22, 2019 • 3:00 PM - 3:55 PM

BUSINESS PANEL

California East Room

Recruiting Talent to Meet Corporate Board Requirements and Representation Goals

Moderator: Cissy S. Young, PhD, *Managing Director, Russell Reynolds Associates*

Panelists: Matthew Fust, *Independent Advisor to Life Sciences Companies*

KT Moortgat, PhD, *Director, AbbVie Ventures*

William J. Newell, *Chief Executive Officer, Sutro Biopharma*

Amanda K. Packel, JD, *Managing Director, Rock Center for Corporate Governance at Stanford University*

By the end of 2019, publicly traded companies in California must have at least one woman director and those targets will increase by 2021. Massachusetts, Pennsylvania, and New Jersey along with other states have considered similar targets which will impact the biotechnology industry. As start-ups and small and medium sized biotech companies consider company growth and future exits, starting early with inclusive hiring practices and board recruitment has become a business priority. Attend this session to gain insight on corporate governance best practices and tips on conducting searches for companies to remain innovative and competitive in this changing environment. Resources for leadership teams and boards will be shared including tools created as part of BIO's recently launched "Right Mix Matters" campaign.

Tuesday, October 22, 2019 • 4:00 PM - 4:55 PM

BUSINESS PANEL

California East Room

View from the Board: To IPO Now or Not?

Moderator: Michael O'Donnell, *Partner, Morrison & Foerster LLP*

Invited Panelists: Linda Grais, MD, *Former CEO, Ocera Therapeutics*

Chris Lowe, *Chief Financial Officer, Cortexyme*

Saira Ramasastry, *Managing Partner, Life Sciences Advisory*

With uncertain market conditions and concerns about realistic valuation expectations, innovative biotechs are trying to pinpoint the right time to go public. The right executive team and a clear, strategic roadmap have become more imperative as companies continually receive mixed signals from potential bookrunners and concerns are raised over IP in course of making a compelling case for going public and gaining access to capital markets. This panel will review how to structure those conversations and decisions around the current landscape and be as productive as possible toward timing the market accurately for a future IPO.

Tuesday, October 22, 2019 • 5:30 PM - 6:30 PM

WELCOME RECEPTION

Mission Bay, 32nd Floor



Wednesday Schedule of Events

Schedule subject to change and speakers continue to be updated.

To see the full list of speakers, please visit <http://bit.ly/BIF19speakers>

Wednesday, October 23, 2019	
6:30 AM - 5:30 PM	Partnering Customer Service Desk Sussex Room
6:50 AM - 5:00 PM	Satellite Partnering Desk 3rd & 4th Floor
7:00 AM - 7:55 AM	Networking Breakfast California West Room
7:00 AM - 5:00 PM	Partnering Meetings 3rd & 4th Floor
7:00 AM - 4:30 PM	Partnering Hospitality Suite Room 334
9:00 AM - 3:45 PM	Company Presentations Elizabethan Rooms A-D & Yorkshire Room

Sessions at a Glance	
8:30 AM - 9:40 AM	Progress in CNS Drug Development Outside Dementia
9:45 AM - 10:40 AM	Advice on Pitching to Family Offices, Venture Philanthropies and Other Non-Private Equity Funding Sources
10:45 AM - 11:40 AM	Molecular Diagnostics: Drivers of New Investor Interest and Reimbursement Success
12:00 PM - 1:25 PM	Fireside Chat: Wende Hutton, General Partner, Canaan
1:45 PM - 2:40 PM	Separating Artificial Intelligence Hype from the Real Utility in Drug Development
2:45 PM - 3:55 PM	Best Practices in Biopharma Alliances with Digital Therapeutics Partners
4:00 PM - 4:55 PM	Market Outlook - Taking the Temperature of the IPO Market in an Era of Large Pharma M&A

Wednesday, October 23, 2019 • 8:30 AM - 9:40 AM

THERAPEUTIC PANEL

California East Room

Progress in CNS Drug Development Outside Dementia

Panelists: Alice Chen, PhD, *Vice President, Accelerator Life Science Partners*
Tao Huang, PhD, JD, *Venture Partner, Cenova Capital*
Ellen Lubman, *Chief Business Officer, Impel NeuroPharma*
Robert Molinari, PhD, *Founder and CEO; Director, Retrotope*

Recent studies from the National MS Society have estimated that nearly one million people in the United States are suffering from Multiple Sclerosis. Millions more suffer from schizophrenia, and thousands more from other CNS disorders that remain without a cure. In order to address the unmet medical needs of this patient population, dozens of companies from across the biotechnology industry are involved in late-phase clinical trials that are exploring the efficacy of different drug treatments on a variety of CNS disorders. On the investment side of the equation, neurology companies had the third highest number of biopharma deals in the first half of 2019, with over \$800 million invested, according to the Silicon Valley Bank Mid-Year Report 2019. Hear from researchers and biotech executives involved in CNS drug development to gain insight into how the industry is expanding and the current clinical trials that have the potential to provide life-changing therapeutic solutions.

Wednesday, October 23, 2019 • 9:45 AM - 10:40 AM

BUSINESS PANEL

California East Room

Advice on Pitching to Family Offices, Venture Philanthropies, and Other Non-Private Equity Funding Sources

Moderator: Maura Little, *Executive Director, Cambia Grove*

Panelists: Deanna Belsky, PhD, *Associate, Dolby Family Ventures*
Bob Crutchfield, *Managing Director, BrightEdge Ventures*
Reza Halse, PhD, *Vice President and Head, BD&L Pacific Innovation Hub and President, MRL Ventures Fund, Merck & Co., Inc.*
Charlotte Hubbert, PhD, *Partner, Gates Foundation Venture Capital*
Peter Lomedico, *Senior Advisor, T1D Fund, JDRF*
Christopher Penland, PhD, *Vice President of BioPharma Programs, Cystic Fibrosis Foundation*

With investment on the rise and the biotechnology industry continuously providing enormous reward opportunities, the demographic of investors has started to shift from the typical stakeholder. How should CEOs approach these potential partners and successfully secure a funding round? This session will feature experienced voices explaining the strategies to employ to properly satisfy a potential investor's expectation and secure the desired capital.

Wednesday, October 23, 2019 • 10:45 AM - 11:40 AM

THERAPEUTIC PANEL

California East Room

Molecular Diagnostics: Drives of New Investor Interest and Reimbursement Success

Moderator: Benjamin Soule, MD, *Global Search and Evaluation Lead—Business Development, Bristol-Myers Squibb*

Panelists: Alexis Ji, PhD, *Partner, Illumina Ventures*

Trevor Martin, *Co-Founder and CEO, Mammoth Biosciences*

Richard J. Wenstrup, MD, *Chief Medical Officer, Epic Sciences*

As the biotechnology industry continues to address unmet medical needs across a wide variety of diseases and disorders, emerging innovative diagnostics methods are paving the way for earlier detection and increased levels of response to treatment. Companion and molecular diagnostics offer advanced methods of identifying biomarkers for cancer and other diseases and allow for the application of bespoke immune-based therapies. Additionally, Diagnostics Analytics deals spiked in the first half of 2019, with 119 deals totaling \$2.164 billion, and are predicted to continue a three-year upward trend, according to the Silicon Valley Bank Mid-Year Report 2019. This panel explores the novel drug and product development from diagnostics companies in the industry that drive funding and reimbursement.

Wednesday, October 23, 2019 • 9:40 AM - 10:15 AM

MORNING NETWORKING REFRESHMENTS

California West Room

Wednesday, October 23, 2019 • 12:00 PM - 1:25 PM

PLENARY LUNCHEON

Grand Ballroom, Mezzanine Floor



Fireside Chat: Wende Hutton, General Partner, Canaan

Moderator: Chris Ehrlich, *Managing Director, Global Head of Biopharma, Locust Walk*

Wednesday, October 23, 2019 • 1:45 PM - 2:40 PM

THERAPEUTIC SESSION

California East Room

Separating Artificial Intelligence Hype from Real Utility in Drug Development

Panelists: Josep Bassaganya-Riera, DVM, PhD, *Chairman and CEO, Landos Biopharma*
Gini Deshpande, PhD, *Founder & Chief Executive Officer, NuMedii*
Bill Martin, PhD, *President and Chief Operating Officer, Blackthorn Therapeutics*
Krishnan Nandabalan, PhD, *President and CEO, InveniAI*

Recent data shows venture investment in AI-focused biopharma companies reached a new high of \$1.4B through the first half of this year, according to CB Insights. However, the wide variance in applications and algorithms has complicated the ability to map progress in drug development techniques. As leaders in this space now begin to point to molecules moving into development and early clinical results, the prioritization of tools for other biotechs to consider adopting becomes clearer. This session will examine where AI can improve current drug discovery and development versus technological promises that are still years away from delivery.

Wednesday, October 23, 2019 • 2:30 PM - 3:00 PM

AFTERNOON NETWORKING REFRESHMENTS

California West Room



Wednesday, October 23, 2019 • 2:45 PM - 3:55 PM

THERAPEUTIC PANEL

California East Room

Best Practices in Biopharma Alliances with Digital Therapeutics Partners

Moderator: Megan Zweig, *Head of Research, Rock Health*

Invited: Panelists: David B. Klein, *Chairman, President & CEO, Click Therapeutics*

Javier Garcia Palacios, PhD, *Director Digital Health Ventures #G4A, Bayer*

Lucia Savage, *Chief Privacy and Regulation Officer, Omada Health*

Ruchita Sinha, *Senior Director of Investments, Sanofi Ventures*

As the FDA has standardized the approval pathway for digital therapeutics, an increasing number of such therapies are reaching patients, often in collaboration with existing biopharma companies. Rock Health released an in-depth study earlier this year identifying four success factors that must be shared for such partnerships: value proposition of the project, organizational commitment, evidence standards, and channel strategy with business model. This session will feature Rock Health's specific data then discuss the opportunities and challenges with digital therapeutics and biopharma alliance partners themselves.

Wednesday, October 23, 2019 • 4:00 PM - 4:55 PM

BUSINESS PANEL

California East Room

Market Outlook – Taking the Temperature of the IPO Market in an Era of Large Pharma M&A

Moderator: Greg Wade, PhD, *Managing Director, Healthcare Investment Banking, BTIG*

Panelists: Shawn Cross, *Managing Director, Healthcare Investment Banking, JMP Securities*

James Healy, MD, PhD, *General Partner, Sofinnova*

Margaret Kim, *Executive Director, Life Sciences, JPMorgan Chase & Co.*

John Kollins, *President & Chief Executive Officer, Satsuma Pharmaceuticals*

Bibhash Mukhopadhyay, PhD, *Principal, New Enterprise Associates*

Megan Zweig, *Head of Research, Rock Health*

As we start to close out 2019, the mixed signals regarding the appetite for IPOs are off from 2018's strong finish. This year's 33 offerings in the 1H have totaled \$2.992 billion, compared to the \$3.484 billion seen in the 35 offerings from last year. Large pharma M&A deals, however, continue to surprise and raise questions about a temporary market shift or a lasting trend. Are venture funding trends being affected by IPO success rates? With market volatility also on the rise aided by continued global trade tensions, the second half of 2019 raises concerns about the endurance of high valuations. This session will examine the path forward while highlighting the availability of quality targets for funding and the patterns of exits in the market.

2019 Participating Investors*

Below is a representative list of participating investment firms and sell side research analysts for the 2019 BIO Investor Forum.

3E Bioventures	Cipla	Johnson & Johnson	Qiming Venture Partners VSA
AbbVie	Coventry Enterprises	Development Corporation	Quadrige Biosciences
ABES Venture Partners	Cowin Capital	Joyance Partners	Quan Capital
Abingworth Management	Crosswave Management	Julz Co	RBV Capital
Accelerator Life Science Partners	CRV	Juvenile Diabetes Research Foundation (JDRF)	Relentless Pursuit Partners
Acuris Partners	CSC Leasing	KB Financial Group	Remiges Ventures
Adjuvant	Dabar Investment Associates	Kyoto University Innovation Capital	Research Bridge Partners
Agent Capital	Dalton Investment	Laguna Ventures	Roche Venture Fund
Agilent Technologies	Danaher Life Sciences	Laurel Venture Capital	Sanderling Ventures
Aleph Capital	Data Collective Venture Capital	Life Science Angels	Sandhill Angels
Alexandria Venture Investments	DAYLI Partners	Lilly Asia Ventures	Sanofi
Alignment Ventures	DCVC Bio	Lincoln Park Capital	Santen Pharmaceutical Co.
Altamont Pharmaceutical Holdings	Defta Partners	Lumira Ventures	Santen Ventures
Altitude Life Science Ventures	DHVC	Lyfe Capital	Satter Medical Technology Partnership
Andreessen Horowitz	DigiTx Partners	Lymo Ventures	Shanghai Henlius Biotech
Aquila Capital	Dolby Family Ventures	LYZZ Capital Advisors	Shenzhen Salubris Pharmaceuticals
Arch Venture Partners	Dorset Capital	Matthews Asia	Simcere Pharmaceutical Group
Arix Bioscience	DoubleLine Capital	Matthews International Capital Management	Sinar Mas Technology
ARTIS Ventures	Dynamk Capital	Maywell Capital	Sofinnova Ventures
Asahi Kasei America	East West Bank	MDB Capital Group	SPRIM Ventures
Asajes Medical	Eisai	MedImmune Ventures	SR One
Asajes Ventures	Emerson Collective	Milestone Capital	StarLink Capital
Asset Management Ventures	Esousa Holdings	Mitsui & Co. Global Investment	StartUp Health
Astellas Innovation Management	FMG Ventures	Momentum Biotech	Steel Wolf Ventures
Astellas Pharma US	F-Prime Capital Partners	MPM Capital	Taiho Ventures
Astellas Venture Management	Fujifilm Diosynth Biotechnologies	MSQ Ventures	Taiwania Capital
ATEL Ventures	G4S Capital	MyBioGate	Takeda Ventures
Atheneos Ventures	GE Ventures	Nan Fung Life Sciences	Talfinium Investments
Band of Angels	Genoa Ventures	NanoDimension	The Benchmark Company
Barbara Lavery	Global Neurohealth Ventures	NCL Technology Ventures	The Leukemia & Lymphoma Society
Beacon Capital	GreenSky Capital	New Enterprise Associates (NEA)	Tosoh USA
Biocoast Capital	Grey Sky Venture Partners	Nomura Instinet	TransPacific Venture Capital Partners
Bioldeations	Hannol Ventures	Northern Light Venture Capital	Triple Ring Technologies
Biomark Capital	Hbm Partners	Novo Ventures (US)	Ultrum Capital
BioPacific Investors	HCM Healthcare Capital Management	OCV	VantagePoint Capital Partners
Bios Partners	HealthCare Royalty Partners	Olive Tree Capital	venBio Partners
Biotech Alliances International	HEDA Ventures	Oresund Capital	Vertex Venture Holdings
Bohe Angel Fund	Helicase Venture	OSF Healthcare Ventures	Vivo Capital
Borex Capital	Helix Ventures	Otsuka Pharmaceutical Co.	Voya Financial
Boryung Holdings	Hemi Ventures	Oxford Finance	W Global Capital
BOSON Capital Partners	Hercules Capital	Palo Alto Investors	WARF Therapeutics
Brace Pharma Capital	Hone Capital	Panacea Venture Healthcare	Washington Research Foundation Center
Brain Trust Accelerator Fund	Iaso Ventures	Pappas Ventures	WBB Securities
BridgeBio Pharma	Illumina Accelerator	Perserverance Capital	Westlake Ventures
BTIG	Illumina Ventures	Pharmstandard JSC	WI Harper Group
Canadian Imperial Bank of Commerce	In Capital	Pivotal BioVenture Partners	Xeraya Capital Life Venture
Capital Family Office	Inbio Ventures	PoC Capital	Y Combinator
Cato BioVentures	INCOJ	Premier Partners	Yonjin Capital
CEC Capital	Integral Group	Presidio Partners	Yuhan USA
Genova Capital	Intuitive	Prevail Partners	ZGC Capital
Chaperone Investment	IPF Partners	Primer Capital	ZJ Future
China Grand	JHBio		
CI Investments			

*As of 10/07/2019

2019 Participating Companies*

360MEDLINK	Bird Rock Bio	Drusolv Therapeutics	Informa
712 North	BlackThorn Therapeutics	Dyadic International	InMed Pharmaceuticals
A2A Pharmaceuticals	Bloom Science	Dyve Biosciences	Innofly Management
Abalone Bio	Boundless Bio	EA Pharma	Innovate Biopharmaceuticals
Abreos Biosciences	Brava Diagnostics	Economic Development Agency	Intabio
Accelero Biostructures	Breakthrough Genomics	Brandenburg	Interface Biologics
Accutis	BridgeBio Pharma	Edesa Biotech	InterVenn Biosciences
Acquist Therapeutics	BridGene Biosciences	Elevian	InveniAI
ACS Brightedge Fund	Bristol-Myers Squibb Company	Elex Biotech	Inversago Pharma
ACT Genomics	Business France	Eli Lilly and Company	Invivo Sciences
Actinium Pharmaceuticals	California Institute for	EngineBio	ISOThrive
ActoBio Therapeutics	Regenerative Medicine	Engrail Therapeutics	Jaan Biotherapeutics
Adjuvance Technologies	Cambia Grove	Ensysce Biosciences	JT Pharma
Aethlon Medical	Canaccord Genuity	EnterTroy Bio	Kaléo Pharma
Ahead Therapeutics SL	Cantabio Pharmaceuticals	Epic Sciences	Kedalion Therapeutics
AIMM Therapeutics	Cardiogas Technologies	Epilepsy Foundation	Kelun Pharmaceuticals
AiVita Biomedical	Caribou Biosciences	Equillum	Kezar Life Sciences
Allen Institute For Brain Science	Carmell Therapeutics	Espero BioPharma	Kineta
Allogene Therapeutics	Catalyst Pharmaceuticals	ethris GmbH	Kinoxis Therapeutics
Alpha Cancer Technologies	Cell Care Therapeutics	Eureka Therapeutics	Kissei America
Alpine Immune Sciences	Celularity	Evaluate	Kleo Pharmaceuticals
Altimmune	Century Therapeutics	Exicure	KPI Therapeutics
American Gence Technologies	Cerevance	Exxel Pharma	Kyorin USA
International	CerSci Therapeutics	Facile Therapeutics	L.E.K. Consulting
Amma Therapeutics	Cesca Therapeutics	Fellow Health	Landos Biopharma
Amnicell	Chubb	Fenologica Biosciences	LaVoieHealthScience
AMPsource Biopharma	Circle Pharma	Fibrocell Science	Leibniz Institute on Aging
AMRA Medical	Circumvent	First Light Diagnostics	Leidos
Amygdala Neurosciences	City of Hope	Foresee Pharmaceuticals	Lempo Therapeutics
Anima Biotech	Click Therapeutics	Fortress Biotech	Lexent Bio
Annexon Biosciences	Clinical Network Services (CNS)	Galimedix Therapeutics	LIPAC Oncology
Antev	CODA Biotherapeutics	Gel4Med	Locana
Antidote Technologies	CohBar	GLAdiator Biosciences	Locust Walk
Aon Risk Solutions	Common Pharma	GlobalConnectWorks	Lonza Pharma & Biotech
Aposense	Contraline	GlobalData	LSA
Arcturus Therapeutics	Correlia Biosystems	GlyTech	Lung Therapeutics
Ardigen	Cortexyme	Golden Biotechnology Corp.	Lunit
Aristea Therapeutics	Corvidia Therapeutics	Greenwich LifeSciences	Lynx Biosciences
Aro Biotherapeutics	Courier Therapeutics	H.C. Wainwright & Company	MacDougall Biomedical
Aspect Biosystems	Cue Biopharma	Halloran Consulting Group	Communications
AstraZeneca	Cystic Fibrosis Foundation	Halo Biosciences	MAIA Biotechnology
Attentive Therapeutics	CytoDyn	Haystack Sciences	Mammoth Biosciences
Auransa	Cytonus Therapeutics	Heartseed	Mandalmed
Aurora Bio	Cytovia Therapeutics	Helixmith Co.	Mantra Bio
Avail Bio	Da Volterra	Hercules Capital	MaxCyte
Avails Medical	Dalriada Therapeutics	Histogen	Medsavana
Avisa Pharma	Dalton Bioanalytics	Honeylab	Membio
AxeroVision	Daré Bioscience	Hyaloric Biotech	Merck KGaA
Bastion Biologics	Deallus Consulting	Hygieia Biological Laboratories	Metocela
BCell Solutions	DeBiopharm International	IACTA Pharmaceuticals	MetVital
Bilix	Deciduous Therapeutics	Illumina Ventures	MicroRadical 360
Bill and Melinda Gates Foundation	Decoy Biosystems	Ilya Pharma	Mitsubishi Tanabe Pharma
BioCentury	Deep Lens	ImmunoMet Therapeutics	MMSC
BioMarker Strategies	DelNova	Immunophotonics	Molecular Theranostics
BioMotiv	Delta-Fly Pharma	Impact Therapeutics	Monash University
BioSuperior Technology	Demuris	Impel NeuroPharma	Morphocell Technologies
Bioxceed Innovation Hub	Dia-beat-it	IMV	Morrison & Foerster
BioXcel Therapeutics	DNALite Therapeutics	InCarda Therapeutics	MUSC Foundation for Research
Bipharm	DOTBIO	Incysus Therapeutics	Development

*As of 10/07/2019

2019 Participating Companies CONTINUED

Mycovia Pharmaceuticals	OrthoTrophix	Stanford SPARK Program	University of California, San Francisco
Nammi Therapeutics	OxSonics Therapeutics	Stanford University	University of Colorado Anschutz Medical Campus
Nanostics	OxStem Limited	Sterling Bay	University of Michigan
National Institutes of Health, NHLBI	Pacylex Pharmaceuticals	Stero Therapeutics	University of Oslo
National Taiwan University College of Medicine	PAION AG	Structure Based Design	University of Texas at Austin
Navidea BioPharmaceuticals	Panjab University	Summit Therapeutics	University of Texas, MD Anderson Cancer Center
Navigant Consulting	Paras Biopharmaceuticals Finland Oy	Surrozen	University of the Sunshine Coast Clinical Trials Centre
Navigen Pharmaceuticals	Phanes Therapeutics	Symvivo Corporation	University of Tsukuba
NB Health Laboratory	Phenomic AI	SynDevRx	University of Utah TVC
NDA Group	Phosplatin Therapeutics	SyntheX	Univfy
Nelum	Privo Technologies	Tampere University	Unnatural Products
NeOnc Technologies	Proteina	TargetGene Biotechnologies	Valitor
Neumentum	Quadriga Biosciences	Technology Venture Commercialization	Valley Fever Solutions
NeuroBo Pharmaceuticals	Rafael Pharmaceuticals	TEGA Therapeutics	Valtari Bio
Neurocycle Therapeutics	Rakuten Medical Japan K.K.	Teikoku Pharma USA	Vaporox
Neuroscience Trials Australia	Rejuvenation Technologies	Tempo Therapeutics	Varsona Pharmaceuticals
Neuroscientific Biopharmaceuticals	Resverlogix Corporation	Terran Biosciences	VelosBio
New Orleans Business Alliance	Retrotope	Terumo BCT	Venture Valuation
New5win	Riptide Bioscience	The Money Channel NYC	Vida Strategic Partners
Nikon Instruments	RubrYo Therapeutics	The University of Chicago	viDA Therapeutics
Nkarta Therapeutics	SAB Biotherapeutics	The University of Texas MD Anderson	Vigeo Therapeutics
North Carolina Biotechnology Center	Sapience Therapeutics	TheraTarget	Viramal
Novelogs Biotechnology	Satellos Bioscience	ThinkCyte	Vistara Biosciences
Novotech	Satsuma Pharmaceuticals	Thrombo Therapeutics	VitriVax
Nucleus Network	SCIBAC	Tierra Biosciences	VM Oncology
NuvOx Pharma	Seelos Therapeutics	TIGAR Health	Vona Oncology
Okava Pharmaceuticals	SEngine Precision Medicine	Torreya	Vybion
Omada Health	SENS Research Foundation	Tosk	Wenbli Therapeutics
Oncolytics Biotech	Senti Biosciences	Traffic Therapeutics	Wheelhouse
Oncolyze Therapeutics	Sentien Biotechnologies	Tranquis Therapeutics	xCella Biosciences
Oncomatrix Biopharma	Serimmune	Trilogy Therapeutics	Xoc Pharmaceuticals
OncoSenX	SFA Therapeutics	Triursus Therapeutics	Xontogeny
Opiant Pharmaceuticals	ShareVault	TrovaGene	X-Therma
Opus Biotech Communications	Shifa Biomedica Corporation	True Bearing Diagnostics	Yiviva
Oragenics	Shinkei Therapeutics	Tulane University School of Medicine	Zenith Epigenetics
Orion Biotechnology	Siragen Pharmaceuticals	U.S. Pharmacopeial	Zenopharm
OrthoMed	Sisu Pharma	UC Davis-Office of Research	
Orthopaedic Research and Education Foundation	SmartPharma Therapeutics	Ultivue	
	Sofinnova Ventures	University of California, Davis	
	Spectrum Pharmaceuticals		
	SpinalCyte, LLC		
	Splash Pharmaceuticals		

Presenting Companies

CARDIOVASCULAR

Bilix
Brava Diagnostics, Inc.
Elex Biotech, Inc.
InvivoSciences Inc.
Jaan Biotherapeutics LLC
RCE Technologies, Inc.
Resverlogix Corp. (TSX:RVX)
Shifa Biomedical Corporation

CNS/NEUROLOGICAL

712 North
Abreos Biosciences, Inc.
Amygdala Neurosciences
Attentive Therapeutics
BioTrillion
BioXcel Therapeutics (NASDAQ:BTAL)
Cantabio Pharmaceuticals
Cerevance, Inc.
Circumventv
EnterTroy Bio
Epilepsy Foundation
Exicure (NASDAQ:XCUR)
MetVital, Inc.
NeuroScientific Biopharmaceuticals Ltd (ASX:NSB)
SHINKEI Therapeutics
Terran Biosciences
Vybion, Inc.
Xoc Pharmaceuticals, Inc.

DERMATOLOGY

Accutis, Inc.
Dyve Biosciences

DIAGNOSTICS

Breakthrough Genomics
Interpace Diagnostics (NASDAQ:IDXG)
Molecular Theranostics, LLC
Nanostics Inc
True Bearing Diagnostics, Inc

DIGITAL HEALTH

Dalton Bioanalytics
Deep Lens, Inc.
Univfy

GASTROINTESTINAL

Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT)
ISOThrive LLC
OrphoMed, Inc.

GENE/CELL THERAPY

Aivita Biomedical
American Gene Technologies
Caribou Biosciences
Cytonus Therapeutics Inc.
Ilya Pharma
Lempo Therapeutics
MaxCyte, Inc. (LSE | AIM:MXCT)
Senti Biosciences
Sentien Biotechnologies, Inc.
SmartPharm Therapeutics

IMMUNOLOGY

BCell Solutions, Inc.
Kineta, Inc.
Landos Biopharma
Leidos (NYSE:LDOS)
Serimmune, Inc.
Traffic Thera

INFECTIOUS DISEASES

Adjuvance Technologies Inc.
Avails Medical, Inc.
First Light Diagnostics
Mycovia Pharmaceuticals
SciBac Inc.
Summit Therapeutics (NASDAQ:SMMT)

INFLAMMATION

Acquist Therapeutics, Inc.
ActoBio Therapeutics, Inc.
Aristea Therapeutics
Lupa Bio, Inc.
SFA Therapeutics

MEDICAL DEVICES

Aethlon Medical, Inc. (NASDAQ:AEMD)
Azure8
Vaporox

METABOLIC DISEASES

Bird Rock Bio, Inc.
CohBar (NASDAQ:CWBR)

MULTIPLE THERAPEUTICS

Altimmune Inc. (NASDAQ:ALT)
Aptorum Group Limited (NASDAQ: APM)
Synthetic Biologics, Inc. (NYSE:SYN)

ONCOLOGY

ACT Genomics
Actinium Pharmaceuticals, Inc. (NYSE:ATNM)
Aegle Therapeutics Corp.
AIMM Therapeutics
Antev Ltd
BioMarker Strategies, LLC
Bipharma LLC
Boundless Bio, Inc.
Cytovia Therapeutics
DotBio Pte. Ltd.
Foresee Pharmaceuticals Co., Ltd. (TPEX:6576)
GLadiator Biosciences
Golden Biotechnology Corp. (OTC Taipei Exchange:4312)
Greenwich LifeSciences
ImmunoMet Therapeutics
Impact Therapeutics
IMV Inc. (NASDAQ:IMV)
Incysus Therapeutics, Inc.
InterVenn Biosciences
Kleo Pharmaceuticals
MAIA Biotechnology, Inc.
Mantra Bio
Nammi Therapeutics, Inc.
NaNotics, LLC
NeOnc Technologies Inc
Nurix Therapeutics, Inc.
Oncolytics Biotech Inc. (NASDAQ:ONCY)
OncoSenX
Oragenics, Inc.
Orion Biotechnology Canada
OxSonics Therapeutics
Pacylex Pharmaceuticals, Inc.
Phanes Therapeutics, Inc.
Phosplatin Therapeutics
Rakuten Medical
Riptide Bioscience, Inc.
RubrYc Therapeutics, Inc.
Sapience Therapeutics, Inc.
Splash Pharmaceuticals, Inc.

SynDevRx, Inc.

SyntheX
TheraTarget
Vigeo Therapeutics, Inc.
VM Oncology
xCella Biosciences
Zenith Epigenetics
Zenopharm, LLC

OPHTHALMOLOGY

AxeroVision, Inc.
Drusolv Therapeutics
IBI
Palatin Technologies (NYSE: PTN)

ORPHAN/RARE DISEASES

Arcturus Therapeutics (NASDAQ:ARCT)
InMed Pharmaceuticals Inc (TSX:IN)
Lung Therapeutics
TargetGene Biotechnologies

OTHER

MandalMed, Inc.
Savanamed
ThromboTherapeutics Inc.

PAIN MANAGEMENT

CerSci Therapeutics
Ensysce Biosciences, Inc.
Neumentum, Inc.
NeuroBo Pharmaceuticals (NASDAQ Capital Markets: NRBO)

PLATFORM FOR THERAPEUTICS

Abalone Bio, Inc.
Anima Biotech Inc.
Antidote
Engine Biosciences
Tierra Biosciences
VISTARA BIOSCIENCE LLC

QUALIFIED CELLS & TISSUES

Membio

REGENERATIVE MEDICINE

Aspect Biosystems
Cesca Therapeutics Inc. (NASDAQ:KOOL)
Heartseed Inc.
Histogen Inc.
Orthopaedic Research and Education Foundation
Satellos Bioscience Inc.

SpinalCyte

Tempo Therapeutics

X-Therma

REPRODUCTIVE/SEXUAL HEALTH

Daré Bioscience (NASDAQ:DARE)

RESPIRATORY

Ethris GmbH

NB Health Laboratory Co., Ltd

TOOLS/DRUG DEVELOPMENT SUPPORT TECH

FenoLogica Biosciences, Inc.

Haystack Sciences

Intabio

Registration and Housing Information

BIO offers a number of ways to conference attendees to save money on their registration fees.

Discounted rates apply to the following:

- Biotech companies that have raised less than \$25 million in capital.
- Presenting companies bringing three or more attendees.
- Companies bringing more than two employees.
- Corporations or other entities that use biotechnology or related technologies for research and development of products or information.
- Academic institutions.

Qualified institutional and
venture investors are eligible for
complimentary registration.

Westin St. Francis Hotel
335 Powell Street
San Francisco, CA 94102

2019 Sponsors

DOUBLE HELIX SPONSORS



SUPPORTING BANK SPONSOR



CONFERENCE SPONSORS



MEDIA PARTNERS



SUPPORTING ORGANIZATIONS

